Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 8, 2014, Pages 1785-1791

  Gaisler Salomon, Inna ^a,c,d   Kravitz, Efrat ^a,b   Feiler, Yulia ^a   Safran, Michal ^a   Biegon, Anat ^a,e   Amariglio, Ninette ^a   Rechavi, Gideon ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

ADAR; Alzheimer's disease; AMPA; ApoE; Caudate; GluA2; Glutamate; Hippocampus; Neurodegeneration; Postmortem; Primer extension; RNA editing

Indexed keywords

ADENOSINE DEAMINASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR SUBUNIT GLUA2; NEURON SPECIFIC ENOLASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ADARB1 PROTEIN, HUMAN; AMPA RECEPTOR; APOLIPOPROTEIN E4; CALCIUM; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; MESSENGER RNA; RNA BINDING PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE FREQUENCY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EDITING; RNA METABOLISM; RNA SEQUENCE; AGED; ALLELE; CELL DEATH; DNA SEQUENCE; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADENOSINE DEAMINASE; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CALCIUM; CAUDATE NUCLEUS; CELL DEATH; FEMALE; HIPPOCAMPUS; HUMANS; MALE; RECEPTORS, AMPA; RNA EDITING; RNA, MESSENGER; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84899946185     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.02.018     Document Type: Article

References (49)

1. Akbarian S., Smith M.A., Jones E.G. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res. 1995, 699:297-304.
2. Barbon A., Vallini I., La Via L., Marchina E., Barlati S. Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following invitro neural differentiation. Mol. Brain Res. 2003, 117:168-178.
3. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
4. Borges K., Dingledine R. AMPA receptors: molecular and functional diversity. Prog. Brain Res. 1998, 116:153-170.
5. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
6. Brusa R., Zimmermann F., Koh D.S., Feldmeyer D., Gass P., Seeburg P.H., Sprengel R. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995, 270:1677-1680.
7. Burnashev N., Monyer H., Seeburg P.H., Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 1992, 8:189-198.
8. Carter T.L., Rissman R.A., Mishizen-Eberz A.J., Wolfe B.B., Hamilton R.L., Gandy S., Armstrong D.M. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage. Exp. Neurol. 2004, 187:299-309.
9. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J.Cell Mol. Med. 2007, 11:1227-1238.
10. Chen C.X., Cho D.S., Wang Q., Lai F., Carter K.C., Nishikura K. Athird member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 2000, 6:755-767.
11. Chen Y., Durakoglugil M.S., Xian X., Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. U.S.A 2010, 107:12011-12016.
12. Cho D.-S.C., Yang W., Lee J.T., Shiekhattar R., Murray J.M., Nishikura K. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J.Biol. Chem. 2003, 278:17093-17102.
13. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J.Neurosci. Res. 2002, 70:462-473.
14. Faul F., Erdfelder E., Lang A.-G., Buchner A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39:175-191.
15. Feldmeyer D., Kask K., Brusa R., Kornau H.C., Kolhekar R., Rozov A., Burnashev N., Jensen V., Hvalby O., Sprengel R., Seeburg P.H. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat. Neurosci. 1999, 2:57-64.
16. Feng Y., Sansam C.L., Singh M., Emeson R.B. Altered RNA editing in mice lacking ADAR2 autoregulation. Mol. Cell Biol. 2006, 26:480-488.
17. Fox N.C., Warrington E.K., Freeborough P.A., Hartikainen P., Kennedy A.M., Stevens J.M., Rossor M.N. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996, 119(Pt 6):2001-2007.
18. Geiger J.R., Melcher T., Koh D.S., Sakmann B., Seeburg P.H., Jonas P., Monyer H. Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 1995, 15:193-204.
19. Hawrylycz M.J., Lein S., Guillozet-Bongaarts A.L., Shen E.H., Ng L., Miller J.A., van de Lagemaat L.N., Smith K.A., Ebbert A., Riley Z.L. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012, 489:391-399.
20. Hideyama T., Yamashita T., Aizawa H., Tsuji S., Kakita A., Takahashi H., Kwak S. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 2012, 45:1121-1128.
21. Higuchi M., Maas S., Single F.N., Hartner J., Rozov A., Burnashev N., Feldmeyer D., Sprengel R., Seeburg P.H. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 2000, 406:78-81.
22. Hollmann M., Hartley M., Heinemann S. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991, 252:851-853.
23. Hume R.I., Dingledine R., Heinemann S.F. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 1991, 253:1028-1031.
24. Ikonomovic M.D., Mizukami K., Davies P., Hamilton R., Sheffield R., Armstrong D.M. The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J.Neuropathol. Exp. Neurol. 1997, 56:1018-1027.
25. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131(Pt 3):665-680.
26. Jonas P., Burnashev N. Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. Neuron 1995, 15:987-990.
27. Jurinke C., Denissenko M.F., Oeth P., Ehrich M., van den Boom D., Cantor C.R. Asingle nucleotide polymorphism based approach for the identification and characterization of gene expression modulation using MassARRAY. Mutat. Res. 2005, 573:83-95.
28. Kawahara Y., Ito K., Sun H., Aizawa H., Kanazawa I., Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004, 427:801.
29. Koren-Michowitz M., Shimoni A., Vivante A., Trakhtenbrot L., Rechavi G., Amariglio N., Loewenthal R., Nagler A., Cohen Y. Anew MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk. Res. 2008, 32:421-427.
30. Kwak S., Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J.Mol. Med. (Berl) 2005, 83:110-120.
31. Kwak S., Nishimoto Y., Yamashita T. Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research. RNA Biol. 2008, 5:193-197.
32. Lee S., Yang G., Yong Y., Liu Y., Zhao L., Xu J., Zhang X., Wan Y., Feng C., Fan Z., Luo J., Ke Z.J. ADAR2-dependent RNA editing of GluR2 is involved in thiamine deficiency-induced alteration of calcium dynamics. Mol. Neurodegener. 2010, 5:54.
33. Levanon E.Y., Hallegger M., Kinar Y., Shemesh R., Djinovic-Carugo K., Rechavi G., Jantsch M.F., Eisenberg E. Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res. 2005, 33:1162-1168.
34. Liu S.J., Zukin R.S. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007, 30:126-134.
35. Mann D.M. Pyramidal nerve cell loss in Alzheimer's disease. Neurodegeneration 1996, 5:423-427.
36. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
37. Mattson M.P., Guthrie P.B., Kater S.B. Intrinsic factors in the selective vulnerability of hippocampal pyramidal neurons. Prog. Clin. Biol. Res. 1989, 317:333-351.
38. Palmer A.M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?. FASEB J. 1990, 4:2745-2752.
39. Parihar M.S., Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J.Clin. Neurosci. 2004, 11:456-467.
40. Payami H., Kaye J., Heston L.L., Bird T.D., Schellenberg G.D. Apolipoprotein E genotype and Alzheimer's disease. Lancet 1993, 342:738.
41. Paz N., Levanon E.Y., Amariglio N., Heimberger A.B., Ram Z., Constantini S., Barbash Z.S., Adamsky K., Safran M., Hirschberg A., Krupsky M., Ben-Dov I., Cazacu S., Mikkelsen T., Brodie C., Eisenberg E., Rechavi G. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007, 17:1586-1595.
42. Peng P.L., Zhong X., Tu W., Soundarapandian M.M., Molner P., Zhu D., Lau L., Liu S., Liu F., Lu Y. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron 2006, 49:719-733.
43. Riedmann E.M., Schopoff S., Hartner J.C., Jantsch M.F. Specificity of ADAR-mediated RNA editing in newly identified targets. RNA 2008, 14:1110-1118.
44. Rueter S.M., Dawson T.R., Emeson R.B. Regulation of alternative splicing by RNA editing. Nature 1999, 399:75-80.
45. Saunders A., Strittmatter W., Schmechel D., George-Hyslop P.S., Pericak-Vance M., Joo S., Rosi B., Gusella J., Crapper-MacLachlan D., Alberts M. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
46. Valastro B., Ghribi O., Poirier J., Krzywkowski P., Massicotte G. AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice. Neurobiol. Aging 2001, 22:9-15.
47. Valente L., Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 2005, 79:299-338.
48. Valente L., Nishikura K. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. J.Biol. Chem. 2007, 282:16054-16061.
49. Wang L., Swank J.S., Glick I.E., Gado M.H., Miller M.I., Morris J.C., Csernansky J.G. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage 2003, 20:667-682.